Recce Pharmaceuticals Ltd (ASX:RCE) Corrects Quarterly Cash Flow Report
Financial Correction
Recce Pharmaceuticals Limited has issued a correction to its Quarterly Activities/Appendix 4C Cash Flow Report for the quarter ended 31 December 2024. The corrected report reveals net cash inflows from operating activities of A$2.77 million, a change from the previously reported net outflows of A$2.67 million.
Cash Flow Impact
Additionally, the corrected balance of cash at the quarter end is A$6,326,540, up from the originally stated A$1,943,806. The estimated quarters of funding available has been updated to “N/A” due to positive net operating cash inflows. There is no overall impact on the quarter end cash balance.
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.